| Gene Symbol | MAP6 |
| Chromosome | 11q13.2 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | Unlike other MAPs that promote microtubule assembly, MAP6 stabilizes microtubules by preventing depolymerization and protecting them from disassembly under stress conditions[@takemura2018]. |
| Mechanism of Action | Drugs targeting MAP6 would stabilize microtubules through direct binding or modulation of MAP6's stabilizing activity, thereby promoting neuronal cytoskeletal integrity and synaptic function. This stabilization could enhance axonal transport, prevent neuronal degeneration, and support cognitive and synaptic plasticity in neurodegenerative conditions. |
| Primary Expression | neurons throughout development and in adulthood |
| Subcellular Localization | 4. **Proteolytic cleavage**: Specific cleavage generates functional fragments |
| Druggability | Undruggable (0.21) |
| Clinical Stage | Phase II |
| Molecular Weight | 85 kDa |
| Amino Acids | 789 aa |
| Exons | 14 |
| Pathways | Tau-Independent Microtubule Stabilization via MAP6 |
| UniProt ID | Q96JE9 |
| GeneCards | MAP6 |
| Human Protein Atlas | MAP6 |
| Associated Diseases | AD, ALI, Als, AMI, dendritic architecture preservation |
| Known Drugs/Compounds | Paclitaxel (Taxol), Ixabepilone (Ixempra), MAP6-derived peptide stabilizers, Microtubule-associated protein kinase inhibitors |
| Interactions | C1Q, CDK5, CRMP1, HDAC, MAP1A, MAP1B |
| SciDEX Target | View Target Profile (1 clinical trials) |
| SciDEX Hypotheses | Tau/MAP6 antagonism in neurodegeneration progressi Activity-dependent MAP6 scaffolding at synapses Domain boundary cross-talk hypothesis (+2 more) |
| KG Connections | 193 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!